(BHC) Bausch Health Companies - Ratings and Ratios
Prescription,Surgical,Ophthalmology,Contact,Care
BHC EPS (Earnings per Share)
BHC Revenue
Description: BHC Bausch Health Companies
Bausch Health Companies Inc (NYSE:BHC) is a Canadian pharmaceutical company. To evaluate its investment potential, we need to examine its financial health and key performance indicators (KPIs). The companys income tax expense is a crucial aspect to analyze, as it directly impacts its net income.
The pharmaceutical industry is heavily influenced by factors such as research and development (R&D) expenses, regulatory approvals, and patent expirations. BHCs market capitalization is approximately $2.14 billion, indicating a relatively mid-cap company. The price-to-earnings (P/E) ratio is 22.23, which may be considered high compared to some industry peers, suggesting potential overvaluation or high growth expectations.
Key economic drivers for BHC include the demand for its pharmaceutical products, pricing power, and competition. The companys return on equity (RoE) is not available, which is a significant omission, as it is a crucial metric for evaluating profitability. To better understand BHCs financial performance, we need to examine its revenue growth, operating margins, and cash flow generation.
Some essential KPIs to monitor for BHC include revenue growth rate, gross margin percentage, operating cash flow margin, and debt-to-equity ratio. Analyzing these metrics will provide insights into the companys ability to generate cash, manage its debt, and maintain profitability. Additionally, we should track industry trends, such as the adoption of generic drugs and the impact of regulatory changes on the pharmaceutical landscape.
BHC Stock Overview
| Market Cap in USD | 2,646m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1994-03-29 |
BHC Stock Ratings
| Growth Rating | -38.7% |
| Fundamental | 67.5% |
| Dividend Rating | 4.65% |
| Return 12m vs S&P 500 | -19.8% |
| Analyst Rating | 3.0 of 5 |
BHC Dividends
Currently no dividends paidBHC Growth Ratios
| Growth Correlation 3m | 62.1% |
| Growth Correlation 12m | -65.8% |
| Growth Correlation 5y | -74.8% |
| CAGR 5y | -1.30% |
| CAGR/Max DD 3y | -0.02 |
| CAGR/Mean DD 3y | -0.05 |
| Sharpe Ratio 12m | -0.62 |
| Alpha | 0.32 |
| Beta | 0.454 |
| Volatility | 57.28% |
| Current Volume | 3777k |
| Average Volume 20d | 1988.6k |
| Stop Loss | 6.5 (-4.8%) |
| Signal | -0.33 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (98.0m TTM) > 0 and > 6% of Revenue (6% = 589.9m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA 0.70pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 15.65% (prev 9.15%; Δ 6.50pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 1.51b > Net Income 98.0m (YES >=105%, WARN >=100%) |
| Net Debt (20.01b) to EBITDA (2.91b) ratio: 6.88 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.31 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (373.1m) change vs 12m ago 0.78% (target <= -2.0% for YES) |
| Gross Margin 75.37% (prev 92.30%; Δ -16.93pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 36.58% (prev 34.70%; Δ 1.88pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.34 (EBITDA TTM 2.91b / Interest Expense TTM 1.48b) >= 6 (WARN >= 3) |
Altman Z'' -0.34
| (A) 0.06 = (Total Current Assets 6.51b - Total Current Liabilities 4.97b) / Total Assets 27.27b |
| (B) -0.36 = Retained Earnings (Balance) -9.73b / Total Assets 27.27b |
| (C) 0.07 = EBIT TTM 1.98b / Avg Total Assets 26.88b |
| (D) -0.04 = Book Value of Equity -1.01b / Total Liabilities 27.12b |
| Total Rating: -0.34 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 67.53
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield 4.95% = 2.48 |
| 3. FCF Margin 11.41% = 2.85 |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda 7.48 = -2.50 |
| 6. ROIC - WACC (= 9.53)% = 11.91 |
| 7. RoE data missing |
| 8. Rev. Trend 76.36% = 5.73 |
| 9. EPS Trend -8.74% = -0.44 |
What is the price of BHC shares?
Over the past week, the price has changed by -4.48%, over one month by -14.84%, over three months by +19.20% and over the past year by -4.87%.
Is Bausch Health Companies a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BHC is around 6.61 USD . This means that BHC is currently overvalued and has a potential downside of -3.22%.
Is BHC a buy, sell or hold?
- Strong Buy: 0
- Buy: 1
- Hold: 5
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the BHC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.1 | 3.7% |
| Analysts Target Price | 7.1 | 3.7% |
| ValueRay Target Price | 7.3 | 7.2% |
Last update: 2025-09-12 04:32
BHC Fundamental Data Overview
CCE Cash And Equivalents = 1.73b USD (last quarter)
P/E Trailing = 27.5
P/E Forward = 1.7501
P/S = 0.2684
P/B = 18.7773
P/EG = 0.6315
Beta = 0.477
Revenue TTM = 9.83b USD
EBIT TTM = 1.98b USD
EBITDA TTM = 2.91b USD
Long Term Debt = 20.86b USD (from longTermDebt, last quarter)
Short Term Debt = 879.0m USD (from shortTermDebt, last quarter)
Debt = 21.74b USD (Calculated: Short Term 879.0m + Long Term 20.86b)
Net Debt = 20.01b USD (from netDebt column, last quarter)
Enterprise Value = 22.66b USD (2.65b + Debt 21.74b - CCE 1.73b)
Interest Coverage Ratio = 1.34 (Ebit TTM 1.98b / Interest Expense TTM 1.48b)
FCF Yield = 4.95% (FCF TTM 1.12b / Enterprise Value 22.66b)
FCF Margin = 11.41% (FCF TTM 1.12b / Revenue TTM 9.83b)
Net Margin = 1.00% (Net Income TTM 98.0m / Revenue TTM 9.83b)
Gross Margin = 75.37% ((Revenue TTM 9.83b - Cost of Revenue TTM 2.42b) / Revenue TTM)
Tobins Q-Ratio = -22.34 (set to none) (Enterprise Value 22.66b / Book Value Of Equity -1.01b)
Interest Expense / Debt = 2.14% (Interest Expense 465.0m / Debt 21.74b)
Taxrate = 143.1% (set to none) (239.0m / 167.0m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.31 (Total Current Assets 6.51b / Total Current Liabilities 4.97b)
Debt / EBITDA = 7.48 (Net Debt 20.01b / EBITDA 2.91b)
Debt / FCF = 19.38 (Debt 21.74b / FCF TTM 1.12b)
Total Stockholder Equity = -1.10b (last 4 quarters mean)
RoA = 0.36% (Net Income 98.0m, Total Assets 27.27b )
RoE = unknown (Net Income TTM 98.0m / Total Stockholder Equity -1.10b)
RoCE = 10.01% (Ebit 1.98b / (Equity -1.10b + L.T.Debt 20.86b))
RoIC = 9.53% (Ebit 1.98b / (Assets 27.27b - Current Assets 6.51b))
WACC = unknown (E(2.65b)/V(24.38b) * Re(7.69%)) + (D(21.74b)/V(24.38b) * Rd(2.14%) * (1-Tc(none)))
Shares Correlation 3-Years: 51.52 | Cagr: 0.24%
Discount Rate = 7.69% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈1.04b ; Y1≈679.6m ; Y5≈310.8m
Fair Price DCF = 16.52 (DCF Value 6.11b / Shares Outstanding 369.8m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -8.74 | EPS CAGR: 6.57% | SUE: -0.05 | # QB: 0
Revenue Correlation: 76.36 | Revenue CAGR: 7.62% | SUE: N/A | # QB: None
Additional Sources for BHC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle